Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for TransThera Sciences (Nanjing)'s EV-to-FCF or its related term are showing as below:
FRA:J8J'
s EV-to-FCF Range Over the Past 10 Years
Min: -239.68 Med: -72.66 Max: -7.46
Current: -13.12
During the past 3 years, the highest EV-to-FCF of TransThera Sciences (Nanjing) was -7.46. The lowest was -239.68. And the median was -72.66.
FRA:J8J's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 16.05
vs FRA:J8J: -13.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TransThera Sciences (Nanjing)'s PE Ratio (TTM) for today is calculated as:
TransThera Sciences (Nanjing)'s share price for today is €1.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TransThera Sciences (Nanjing)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.092.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TransThera Sciences (Nanjing) EV-to-FCF Related Terms
TransThera Sciences (Nanjing) EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) EV-to-FCF Chart
TransThera Sciences (Nanjing) Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-FCF
0.00
0.00
-160.95
TransThera Sciences (Nanjing) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-FCF
0.00
0.00
0.00
0.00
-160.95
FRA:J8J vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransThera Sciences (Nanjing) EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TransThera Sciences (Nanjing)'s EV-to-FCF falls into.
TransThera Sciences (Nanjing)'s current Enterprise Value is €395.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TransThera Sciences (Nanjing)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-30.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) (FRA:J8J) has a EV-to-FCF of -12.90 as of Aug. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TransThera Sciences (Nanjing) and its competitors. According to the industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 321 companies in the Biotechnology industry.
Is TransThera Sciences (Nanjing)'s EV-to-FCF too high?
TransThera Sciences (Nanjing)'s current EV-to-FCF is -12.90. Based on the distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 321 companies for EV-to-FCF. This places TransThera Sciences (Nanjing) in the lower half of its industry. The industry median EV-to-FCF is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.05, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TransThera Sciences (Nanjing) and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransThera Sciences (Nanjing)'s current EV-to-FCF is -12.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current EV-to-FCF of -12.90. The current EV-to-FCF is -12.90. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current EV-to-FCF is -12.90 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score
Get the complete analysis for FRA:J8J
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8J has been successfully added to your 
